Key Insights

Highlights

Success Rate

83% trial completion

Published Results

12 trials with published results (28%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

11.6%

5 terminated out of 43 trials

Success Rate

82.8%

-3.7% vs benchmark

Late-Stage Pipeline

40%

17 trials in Phase 3/4

Results Transparency

50%

12 of 24 completed with results

Key Signals

12 with results83% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (11)
P 1 (4)
P 2 (7)
P 3 (12)
P 4 (5)

Trial Status

Completed24
Unknown13
Terminated5
Active Not Recruiting1

Trial Success Rate

82.8%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (43)

Showing 20 of 20 trials
NCT05476926Active Not Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05520177Phase 3CompletedPrimary

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

NCT04667897Phase 2CompletedPrimary

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT04740905Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT06146309Not ApplicableCompletedPrimary

Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion

NCT04120311Phase 1Unknown

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636Phase 1Unknown

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT03802630Phase 3TerminatedPrimary

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03054766Not ApplicableCompletedPrimary

Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

NCT00556114Completed

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT02390245Not ApplicableCompleted

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT03108352Phase 3CompletedPrimary

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

NCT05127525Phase 3Terminated

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT03651011Not ApplicableCompletedPrimary

Navigated Laser In Branch Retinal Vein Occlusion Study

NCT01746615Not ApplicableUnknownPrimary

Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects

NCT02503540Phase 4Completed

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT04601688Not ApplicableUnknownPrimary

Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

NCT00500045Phase 2Terminated

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT01795209Phase 4TerminatedPrimary

Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision

NCT02478515Phase 4CompletedPrimary

Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion

Scroll to load more

Research Network

Activity Timeline